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Abstract
Introduction: Cardiac-surgery-associated-acute-kidney-injury (CSA-AKI) is associated with increased morbidity and
mortality. Recent data from patients undergoing on-pump coronary artery bypass grafting suggest that a
perioperative infusion of sodium-bicarbonate may decrease the incidence of CSA-AKI. The present study aims to
analyze the renoprotective effects of a 24h infusion of sodium-bicarbonate in a large, heterogeneous group of
cardiac surgical patients
Methods: Starting in 4/2009, all patients undergoing cardiac surgery at our institution were enrolled in a
prospective trial analyzing the relationship between preoperative cerebral oxygen saturation and postoperative
organ dysfunction. We used this prospectively sampled data set to perform a cohort analysis of the renoprotective
efficiency of a 24h continuous perioperative infusion of sodium-bicarbonate on the incidence of CSA-AKI that was
routinely introduced in 7/2009. After exclusion of patients with endstage chronic kidney disease, off-pump
procedures, and emergency cases, perioperative changes in renal function were assessed in 280 patients treated
with a perioperative infusion of 4 mmol sodium-bicarbonate / kg body weight in comparison with a control
cohort of 304 patients enrolled from April to June in this prospective cohort study.
Postoperative changes in urine flow, plasma creatinine, estimated creatinine clearance, and the need for renal
replacement therapy were determined according to AKI injury network criteria. Concomitantly, hemodynamics,
treatments, complications, and clinical outcomes were recorded. Univariate statistical analyses were performed
para- and nonparametrically, as appropriate.
Results: With the exception of a lower prevalence of a history of myocardial infarction and a lower preoperative
use of intravenous heparin in the bicarbonate-group, no significant between group differences in patient
demographics, surgical risk, type, and duration of surgery were observed. Patients in the bicarbonate group had a
lower mean arterial blood pressure after induction of anesthesia, needed more fluids, more vasopressors, and a
longer treatment time in the high dependency unit. Despite a higher postoperative diuresis, no differences in the
incidence of AKI grade 1 to 3 and the need for renal replacement were observed.
Conclusions: Routine perioperative administration of sodium bicarbonate failed to improve postoperative renal
function in a large population of cardiac surgical patients.
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Introduction
Acute kidney injury (AKI) is a frequent complication in
patients undergoing cardiac surgery [1,2]. With respect
to the multifactorial nature of this complication and the
consequences for short- and long-term prognosis [3]
there is an increasing clinical and scientific interest in
this topic that has now been specifically referred to as
cardiac surgery-associated kidney injury (CSA-AKI) [4].
Recent work suggests that the renal excretion of hemo-
and myoglobin, as a consequence of the destruction of
blood cells during cardiopulmonary bypass and tissue
injury during prolonged periods of hypoperfusion, and
the subsequent development of a pigment nephropathy,
may play a pathophysiologically important role in CSA-
AKI [5]. In support of this concept and with respect to
the fact that urine alkalization with sodium bicarbonate
(BIC) has traditionally been used to ameliorate the conse-
quences of hemo- and myoglobinuria [6], Haase and
coworkers have recently shown that perioperative 24-h
treatment with BIC reduced the incidence of AKI in a
double-blind pilot trial including 100 patients undergoing
on-pump cardiac surgery [7]; findings that are currently
being prospectively validated in 500 patients (the BIC-
NC study; Clinical trials identifier NCT00672334)
With respect to the enormous impact of postoperative
renal dysfunction on outcome in cardiac surgical
patients, the sound pathophysiological basis, and positive
historical experiences with urine alkalization in our cen-
ter we decided not to await the results of the ongoing
multicentre trial and implemented the concept of perio-
perative BIC infusion in July 2009 at our institution.
With respect to the fact that since April 2009 almost all
patients undergoing cardiac surgery at the University of
Lübeck were enrolled in a prospective observational trial
analyzing the association between preoperative cerebral
oxygen saturation and postoperative organ dysfunction,
we chose to use this database also to analyze the effects
of routine BIC application on the perioperative changes
in renal function and the incidence of AKI in this pro-
spective, observational cohort study.
Materials and methods
Following approval by the local ethical committee (Ethik-
kommission der Universität zu Lübeck, Lübeck, Germany),
all patients scheduled for cardiac surgery at the University
of Lübeck from 1 April 2009 to 31 December 2009 were
screened for participation in a prospective, observational
trial on the relationship between preoperative cerebral
oxygenation and postoperative organ dysfunction. The
only exclusion criterion was age less below 18 years. Writ-
ten informed consent was obtained from all elective and
urgent patients as well as emergency patients who were
able to communicate. In the case of sedated and/or
intubated patients scheduled for emergency surgery, con-
sent was obtained from the next of kin and reconfirmed
after recovery.
From July 2009, all patients were treated with a perio-
perative infusion of BIC, and the treatment was maintained
until the first results of the present study were available in
December 2010. Following approval by the local ethical
committee of amendment 5 to the primary request (refer-
ence number, 07-146), we specifically analyzed the perio-
perative changes in renal function and general patient
outcomes according to the use or non-use of BIC. After
exclusion of patients with end-stage chronic kidney disease,
off-pump procedures, and emergency cases, perioperative
changes in renal function were assessed in 280 patients
treated with BIC in comparison with a control cohort
(CON) of 304 patients enrolled from April to June. In addi-
tion to the standard treatment, plasma samples for deter-
mination of N-terminal pro B-type natriuretic peptide
(NTproBNP) and high-sensitivity troponin-T (hsTNT)
were drawn immediately before surgery.
The perioperative infusion of BIC was adapted from
Haase and coworkers [(7)]. A bolus of 0.5 mmol/Kg
body weight (BW) in a balanced electrolyte infusion
(500 ml) was infused within 30 minutes immediately
after induction of anesthesia. Thereafter, a maintenance
infusion of 0.15 mmol/Kg BW/h in 500 ml dextrose in
water (5%) was applied within 24 h, giving a total dose
of 4 mmol BIC/Kg BW during 24 h. Anesthesiological,
surgical, and intensive care treatment followed the stan-
dardized algorithms established at the Department of
Anesthesiology and the Department of Thoracic Vascu-
lar and Cardiac Surgery of the University of Lübeck.
Anesthesiological and intensive care treatments
Following oral premedication with 3.75 to 7.5 mg midazo-
lam, and transfer to the operating room, sensors for the
determination of cerebral oxygen saturation (ScO2) with
an INVOS® 5100 monitor (Somanetics, Troy, MI, USA)
were applied bi-hemisperically before induction of
anesthesia. Baseline ScO2 was determined in the resting
state when breathing room air. General anesthesia was
induced with sufentanil 0.5 μg/Kg BW, etomidate 0.2 to
0.4 mg/Kg BW and maintained at 0.8 to 1.0 minimal
alveolar concentration of sevoflurane and remifentanyl at
0.2 to 0.4 μg/Kg BW/min, with the goal of early postopera-
tive extubation. Muscle relaxation was achieved with
rocuronium bromide 0.6 mg/Kg BW. During cardiopul-
monary bypass (CPB), propofol at a dose of 4 to 5 mg/Kg
BW/h was applied, since at that time volatile anesthetics
could not be given via the CPB circuit. After surgery, all
patients were transferred to the ICU, and after normother-
mia had been achieved, were weaned from the respirator
as soon as possible.
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Hemodynamic therapy aimed at a mean arterial blood
pressure (MAP) between 60 and 90 mmHg, a heart rate
(HR) between 60 and 90 bpm, a central venous pressure
(CVP) between 10 and 15 mmHg, and central venous oxy-
gen saturation (ScvO2) greater than 70%. In patients mon-
itored with a pulmonary artery catheter, hemodynamic
therapy was titrated to achieve a cardiac index > 2.2 l/
min/m2 and mixed venous oxygen saturation (SvO2)
greater than 65% [8]. Pulmonary arterial pressure (PAP)
was used to guide hemodynamic therapy for right heart
and pulmonary vascular function.
Fluid therapy was performed by balanced cristalloid
(Sterofundin ISO 1/1; BBraun; Melsungen, Germany)
and colloidal (Volulyte®, Fresenius, Germany; Gelafun-
din®, BBraun, Melsungen, Germany) fluids, as suggested
by a recent guideline [8].
Surgical and cardiopulmonary bypass treatments
All surgeries were performed with CPB in moderate or
deep hypothermia (according to the preferences of the
surgeon and the scheduled type of surgery). Cardioplegic
arrest was achieved by blood cardioplegia and repeated
every 20 minutes. In coronary-artery bypass grafting
(CABG), a single crossclamp was generally used. Non-pul-
satile perfusion was performed during CPB. Pump flow,
oxygen flow, and MAP were adjusted to maintain ScO2
levels higher than 50% absolute.
Clinical treatments and outcomes
Patients were discharged from the ICU to the intermediate
care unit (IMC) if they were hemodynamically stable with
only moderate inotropic and/or vasopressor support and
were breathing spontaneously without the need for non-
invasive ventilation. They were discharged to the surgical
ward if they had been completely weaned from vasoactive
or inotropic drugs, showed no signs of a relevant organ
dysfunction (that is, pneumonia, AKI, severe neurological
dysfunction, etcetera), and were free of delirium.
A perioperative myocardial infarction was defined as a
relevant increase in myocardial necrosis markers (creati-
nine-kinase and creatinine-kinase MB fraction) in combina-
tion with the development of typical electrocardiographic
findings or the detection of a new wall motion abnormality
by echocardiography.
Indication and performance of renal replacement therapy
Indications for renal replacement therapy were as follows:
potassium equal to or higher than 6 mmol/L despite
forced diuresis or prolonged treatment with glucose-
insulin solution; fluid overload with imminent or present
extrarenal organ dysfunction not responsive to moderate
doses of diuretics (that is, more than 80 mg/d torasemide),
severe low cardiac output state with persistent oliguria
despite, or inadequate reaction to a bolus of a loop diuretic
(furosemide 40 mg, torasemide 20 mg).
Renal replacement therapy was performed as veno-
venous hemodiafiltration in postdilution mode with a
blood flow of 150 to 200 ml/min, an ultrafiltration dose
of 20 ml/Kg BW/h, and a dialysis dose of 15ml/Kg/h.
Statistical analysis
Data entry and analysis were performed with MedCalc
12.1.4. for Windows. Following Kolmogorov-Smirnov test-
ing for normality of distribution, data were analyzed by
parametric and non-parametric tests, as appropriate.
Accordingly, if not stated otherwise, data are presented as
mean and 95% confidence interval for the mean, or median
and 95% confidence interval for the median. A P-value <
0.05 was considered to indicate statistical significance.
The severity of postoperative kidney dysfunction was
quantified according to the criteria of AKI as suggested
by the Acute Kidney Injury Network [9]. Additionally,
and with respect to the ongoing prospective trial on the
effects of BIC on renal function in cardiac surgery
patients (BIC-NC study; Clinical trials identifier
NCT00672334), we determined the number of patients
showing a postoperative increase in plasma creatinine
between 25 and 50%.
Results
Comparability of the study cohorts
With the exception of a lower prevalence of a history of
myocardial infarction (18.6% vs. 26.3%) and a lower preo-
perative use of intravenous heparin in the BIC group, the
study cohorts were highly comparable regarding baseline
demographics, surgical procedures, and surgical core
data (Table 1, 2, and 3). No significant between-group
differences were observed in the additive Euroscore,
plasma levels of NTproBNP, high-sensitivity troponin-T,
creatinine, and estimated glomerular filtration rate
(eGFR) as accepted risk factors for postoperative renal
dysfunction.
Hemodynamics and metabolism
Despite a comparable preoperative baseline, MAP after
induction of anesthesia was significantly lower in the BIC
group. Comparably, mean PAP was lower in these
patients upon arrival on the ICU. No further significant
between-group differences in hemodynamics were
observed (Table 4). Maximal postoperative blood glucose
and lactate levels, as well as maximal Ph, were higher in
the BIC group (Table 5).
Intra- and postoperative treatments
While no significant differences in the need for mechani-
cal circulatory support were observed (Table 2),
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Table 1 Demographic data and preoperative risk stratification






Number 584 304 (52.1%) 280 (47.9%)
Demographics
Age, years 68.5 (67, 69) 68.5 (67, 70) 68.5 (67, 70) 0.675
Male 381 (65.2%) 201 (66.1%) 180 (64.3%) 0.706
Female 203 (34.8%) 103 (33.9%) 100 (35.7%)
Height, cm 171 (170,
172)
171 (170, 173) 171 (170, 172) 0.741
Weight, Kg 81.3 (79.9,
82.6)
82.3 (80.6, 84.1) 80.1 (78.1, 82.1) 0.103
BMI (Kg/m2) 27.2 (26.8,
27.7)
27.4 (26.8, 27.9) 26.9 (26.5, 27.8) 0.098
Cardiovascular risk factors
Diabetes mellitus 158 (27.1%) 72 (23.8%) 86 (30.7%) 0.073
Arterial hypertension 484 (82.9%) 250 (82.2%) 234 (83.6%) 0.751
Smoking (former or present smoker) 246 (42.3%) 125 (41.5%) 121 (43.2%) 0.744
Hyperlipidemia 410 (70.2%) 217 (71.4%) 193 (68.9%) 0.578
Arterial vascular disease 135 (23.1%) 62 (20.4%) 73 (26.1%) 0.127
PAH (systolic > 60 mmHg) (n = 223) 32 (14.3%) 12 (11.1%) 20 (17.4%) 0.252
PAH (systolic > 40 mmHg) (n = 223) 112 (50.2%) 56 (51.9%) 56 (48.7%) 0.736
NYHA I/II 348 (59.6%) 184 (60.5%) 164 (58.6%) 0.692
NYHA III/IV 236 (40.4%) 120 (39.5%) 116 (41.4%)
LVEF < 30% 32 (5.5%) 18 (6.0%) 14 (5.0%) 0.658
LVEF 30 to 50% 139 (24.0%) 68 (22.6%) 71 (25.5%)
LVEF > 50% 408 (70.5%) 215 (71.4%) 193 (69.4%)
ASA 3 (3, 3) 3 (3, 3) 3 (3, 3) 0.801
Add. EuroSCORE 5 (5, 5) 5 (5, 5) 4 (5, 5) 0.455
Add. EuroSCORE 0 to 2 134 (22.9%) 63 (20.7%) 71 (25.4%) 0.300
Add. EuroSCORE 3 to 5 205 (35.1%) 114 (37.5%) 91 (32.5%)
Add. EuroSCORE > 5 245 (42.0%) 127 (41.8%) 118 (42.1%)
Other risk factors
Pulmonary disease 91(15.6%) 46 (15.1%) 45 (16.1%) 0.843
Neurological disease 70 (12.0%) 36 (11.8%) 34 (12.1%) 0.988
Left main stem disease 84 (14.4%) 42 (13.8%) 42 (15.0%) 0.772
Previous cardiac or thoracic vascular surgery 63 (10.8%) 31 (10.2%) 32 (11.4%) 0.730
History of myocardial infarction 132 (22.6%) 80 (26.3%) 52 (18.6%) 0.033
Troponin-T positive status 14 (2.4%) 11 (3.6%) 3 (1.1%) 0.082
History of cardiogenic shock or acute decompensated
heart failure
71 (12.2%) 32 (10.6%) 39 (13.9%) 0.278
Preoperative physiological profile
MAP, mmHg 97 (96, 98) 98 (96, 100) 96 (93, 99) 0.305
Heart rate, bpm 68 (67, 70) 68.5 (67, 70) 68 (67, 70) 0.918
Mean ScO2room, % 63 (62, 63) 62 (62, 64) 63 (62, 64) 0.695
Mean ScO2ox, % 68 (67, 68.17) 68 (67, 69) 68 (67, 69) 0.926
ScO2minox, % 66 (65, 67) 66 (65, 67) 65 (65, 67) 0.924
NTproBNP, pg/ml (n = 389) 455 (355,
519)
392 (312, 496) 517 (391, 686) 0.234
hsTNT, pg/ml (n = 389) 9 (8, 11) 9 (8, 13) 9 (7, 11) 0.850
Demographics, risk factors, and preoperative physiological status are shown for patients undergoing elective, on-pump cardiac surgery with or without a
perioperative infusion of bicarbonate. BMI: body mass index; PAH: pulmonary arterial hypertension; NYHA: New York Heart Association classification; LVEF: left
ventricular ejection fraction; ASA: American Society of Anesthesiology classification; Add.: additive; MAP: mean arterial pressure. ScO2: cerebral oxygen saturation
determined bi-hemispherically by near-infrared spectroscopy; ScO2room: mean of both hemispheres determined when breathing room air; ScO2ox: mean of both
hemispheres determined during application of oxygen-enriched air. ScO2minox: minimal ScO2 from the left or right hemisphere determined during application of
oxygen-enriched air; NTproBNP: N-terminal pro B-type natriuretic peptide; hsTNT: high-sensitivity troponin-T. Data are given as absolute numbers (percentage) for
nominal variables and median (95% confidence interval).
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Table 2 Surgical procedures and performance
Total cohort Control - no bicarbonate Intervention - bicarbonate Significance, P-value
Number 584 304 (52.1%) 280 (47.9%)
Type of procedure
CABG 222 (38.1) 110 (36.3%) 112 (40.0%) 0.160
Valve surgery +/- varia 176 (30.1%) 93 (30.7%) 82 (28.9%)
CABG +/- valve +/- varia 120 (20.6%) 71 (23.4%) 49 (17.5%)
Aortic surgery +/- valve +/- varia 54 (9.3%) 21 (6.9%) 33 (11.8%)
Various procedures 10 (1.7%) 8 (2.6%) 3 (1.1%)
Aortic surgery +/- CABG 2 (0.3%) 1 (0.3%) 1 (0.4%)
Duration of surgery, minutes 254 (247, 261) 249 (242, 260) 258 (250, 268) 0.406
Duration of CPB, minutes 115 (110, 119) 115 9 (107, 122) 115 (109, 120) 0.756
Crossclamp time, minutes 89.5 (84, 93) 88.5 (82, 93) 90 (83, 96) 0.539
ECLS 7 (1.2%) 3 (1.0%) 4 (1.4%) 0.913
IABP
No IABP 556 (95.2%) 289 (95.1%) 267 (95.4%) 0.445
IABP before CPB 6 (1.0%) 2 (0.7%) 4 (1.4%)
IABP during CPB 8 (1.4%) 6 (2.0%) 2 (0.7%)
IABP after CPB 8 (1.4%) 3 (1.0%) 5 (1.8%)
IABP on ICU 6 (1.0%) 4 (1.3%) 2 (0.7%)
Circulatory arrest 21 (3.6%) 13 (4.3%) 8 (2.9%) 0.485
Lowest body temperature, °C 32 (32, 32) 32 (32, 32) 32 (32, 32) 0.615
Surgical procedures and surgical core data are shown for patients undergoing elective on-pump cardiac surgery with or without a perioperative infusion of
bicarbonate. CABG: coronary artery bypass grafting; CPB: cardiopulmonary bypass; ECLS: extracorporeal life support; IABP: intra-aortic balloon pump. Data are
given as absolute numbers (percentage) for nominal variables and as median (95% confidence interval).
Table 3 Preoperative, intraoperative and postoperative therapies
Total cohort Control - no bicarbonate Intervention - bicarbonate Significance, P-value
Number 584 304 (52.1%) 280 (47.9%)
Preoperative treatments
Beta-blocking agents 442 (75.8%) 234 (77.0%) 208 (74.6%) 0.558
ACE-inhibitors/ARB 424 (72.7%) 225 (74.0%) 199 (71.3%) 0.526
Diuretics 328 (56.4%) 173 (56.9%) 155 (55.8%) 0.844
Vasodilators 209 (35.8%) 110 (36.2%) 99 (35.5%) 0.929
Phenprocoumon 11 (1.9%) 4 (1.3%) 7 (2.5%) 0.451
Aspirine 373 (64.1%) 203 (66.8%) 170 (61.2%) 0.185
Clopidogrel 53 (9.1%) 24 (7.9%) 29 (10.4%) 0.366
Heparin, intravenous 95 (16.3%) 62 (20.4%) 33 (11.8%) 0.007
Lipid-lowering drugs 356 (61.1%) 197 (64.8%) 159 (57.0%) 0.065
Insulin 64 (11.0%) 30 (9.9%) 34 (12.2%) 0.446
Antibiotics 64 (11.0%) 33 (10.9%) 31 (11.1%) 0.973
Nitrates, intravenous 29 (5.0%) 17 (5.6%) 12 (4.3%) 0.599
Levosimendan 16 (2.7%) 7 (2.3%) 9 (3.2%) 0.669
Intraoperative fluids
Cristalline fluids, ml 1,948 (1,903, 1,993) 1,982 (,1921, 2,042) 1,911 (1,844, 1,978) 0.120
Colloidal fluids, ml 800 (756, 843) 791 (730, 852) 809 (748, 870) 0.680
Postoperative fluids within 24 h
Cristalline fluids, ml 2,719 (2,667, 2,771) 2,590 (2,519, 2661) 2,859 (2,786, 2,933) < 0.0001
Colloidal fluids, ml 1,476 (1,412, 1,541) 1,404 (1,314, 1,494) 1,555(1,462, 1,647) 0.022
Intraoperative blood transfusion
PRC, patients transfused 314 (53.8%) 166 (54.6%) 148 (52.9%) 0.734
units transfused 1 (0, 1) 1 (0, 1) 1 (0, 1) 0.925
FFP, patients transfused 38 (6.5%) 20 (6.6%) 18 (6.4%) 0.925
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Table 3 Preoperative, intraoperative and postoperative therapies (Continued)
units transfused 0 [0-0] 0 [0-0] 0 [0-0] 0.871
TC, patients transfused 30 (5.1%) 16 (5.3%) 14 (5.0%) 0.965
units transfused 0 (0, 0) 0 (0, 0) 0 (0, 0) 0.980
Cellsaver, number patients 22 (3.8%) 15 (4.9%) 7 (2.5%) 0.185
Postoperative blood transfusion
PRC, patients transfused 253 (43.3%) 129 (42.4%) 124 (44.3%) 0.713
units transfused 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.88) 0.505
FFP, patients transfused 43 (7.4%) 22 (7.2%) 21 (7.5%) 0.971
units transfused 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.907
TC, patients transfused 43 (7.4%) 22 (7.2%) 21 (7.5%) 0.980
units transfused 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.881
Intraoperative vasoactive and inotropic treatments
Levosimendan, n (%) 24 (4.1%) 11 (3.6%) 13 (4.6%) 0.679
Before CPB 23 (3.9%) 11 (3.6%) 12 (4.3%) 0.531
After CPB 1 (0.2%) 0 (0.0%) 1 (0.4%)
Noradrenaline, n (%) 522 (89.4%) 268 (88.2%) 254 (90.7%) 0.386
< 0.3 mg/h 261 (44.7%) 148 (48.7%) 113 (40.4%) 0.069
0.3 to 0.6 mg/h 187 (32.0%) 87 (28.6%) 100 (35.7%)
> 0.6 mg/h 74 (12.7%) 33 (10.9%) 41 (14.6%)
Vasopressin, n (%) 49 (8.4%) 19 (6.2%) 30 (10.7%) 0.073
< 3 U/h 33 (5.7%) 11 (3.6%) 22 (7.9%) 0.109
3 to 6 U/h 15 (2.6%) 8 (2.6%) 7 (2.5%)
> 6 U/h 1 (0.2%) 0 (0.0%) 1 (0.4%)
Dobutamin, n (%) 330 (56.5%) 178 (58.6%) 152 (54.3%) 0.339
< 15 mg/h 130 (22.3%) 70 (23.0%) 60 (21.4%) 0.278
15 to 30 mg/h 170 (29.1%) 96 (31.6%) 74 (26.4%)
> 30 mg/h 30 (5.1%) 12 (3.9%) 18 (6.4%)
PDE-III inhibitors, n (%) 249 (42.6%) 121 (39.8%) 128 (45.7%) 0.174
Low dose 35 (6.0%) 14 (4.6%) 21 (7.5%) 0.126
Moderate dose 198 (33.9%) 96 (31.6%) 102 (36.4%)
High dose 16 (2.7%) 11 (3.6%) 5 (1.8%)
Postoperative vasoactive and inotropic treatment, n (%)
Levosimendan 24 (4.1%) 12 (3.9%) 12 (4.3%) 0.998
Noradrenalin 494 (84.6%) 246 (80.9%) 248 (88.6%) 0.015
< 0.3 mg/h 262 (44.9%) 147 (48.4%) 115 (41.1%) 0.0013
0.3 to 0.6 mg/h 140 (24.0%) 58 (19.1%) 82 (29.3%)
> 0.6 mg/h 92 (15.8%) 41 (13.5%) 51 (18.2%)
Vasopressin 64 (11.0%) 29 (9.5%) 35 (12.5%) 0.312
< 3 U/h 49 (8.4%) 19 (6.2%) 30 (10.7%) 0.116
3 to 6 Uh 13 (2.2%) 8 (2.6%) 5 (1.8%)
> 6 U/h 2 (0.3%) 2 (0.7%) 0 (0.0%)
Dobutamin 386 (66.1%) 207 (68.1%) 179 (63.9%) 0.330
< 15 mg/h 184(31.5%) 97 (31.9%) 87 (31.1%) 0.728
15 to 30 mg/h 164 (28.1%) 90 (29.6%) 74 (26.4%)
> 30 mg/h 38 (6.5%) 20 (6.6%) 18 (6.4%)
PDE III inhibitors 312 (53.5%) 156 (51.3%) 156 (55.9%) 0.304
Low dose 60 (10.3%) 32 (10.5%) 28 (10.0%) 0.665
Moderate dose 224 (38.4%) 110 (36.2%) 114 (40.9%)
High dose 28 (4.8%) 14 (4.6%) 14 (5.0%)
Perioperative pharmacological treatments are shown for patients undergoing elective on-pump cardiac surgery with or without a perioperative infusion of
bicarbonate. ACE-inhibitors: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blocker; PRC: packed red cells; FFP: fresh frozen plasma; TC:
thrombocyte concentrate; PDE-III inhibitors; phosphodiesterase III inhibitors. Data are given as absolute numbers (percentage) for nominal variables, and as
median (95% confidence interval) for non-normally distributed data, and mean (95% confidence interval) for normally distributed variables.
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Table 4 Intraoperative and postoperative hemodynamics
Total cohort Control - no bicarbonate Intervention - bicarbonate Significance, P-value
Number of patients 584 304 280
HR, bpm, preoperative 68 (67, 70) 68.5 (67, 70) 68 (67, 70) 0.875
MAP, mmHg, preoperative 96 (95, 98) 97 (95, 100) 95 (93, 97) 0.396
MAP, mmHg, before induction 85 (82, 85) 87 (85, 90) 80 (76, 83) < 0.0001
MAP, mmHg, 30 minutes before CPB 70 (70, 71) 70 (70, 72) 70 (68, 71) 0.135
MAP, mmHg, 30 minutes after CPB 69 (68, 70) 70 (69, 71) 69 (67, 70) 0.109
MAP, mmHg, end of surgery 72 (71, 73) 73 (71, 74) 71 (70, 73) 0.150
MAP, mmHg, ICU admission 76 (75, 77) 76 (75, 78) 75 (73, 78) 0.339
MAP, mmHg, 2 h after ICU admission 73 (72, 74) 73 (71, 75) 73 (72, 74) 0.833
MAP, mmHg, 4 h after ICU admission 74 (72, 75) 74 (72, 76) 73 (72, 74) 0.541
MAP, mmHg, 6 h after ICU admission 73 (73, 74) 74 (73, 75) 73 (72, 75) 0.361
MAP, mmHg, 8 h after ICU admission 74 (73, 75) 74 (72, 75) 74 (72, 75) 0.632
CVP, mmHg, after induction 11 (10, 11) 11 (10, 11) 11 (10, 12) 0.340
CVP, mmHg, 30 minutes before CPB 8 (8, 8) 8 (8, 9) 8 (7, 9) 0.561
CVP, mmHg, 30 minutes after CPB 11 (10, 11) 10 (10, 11) 11 (10, 12) 0.663
CVP, mmHg, end of surgery 12 (11, 12) 12 (11, 12) 12 (11, 12) 0.396
CVP, mmHg, ICU admission 15 (15, 16) 16 (15, 16) 15 (15, 16) 0.689
CVP, mmHg, 2 h after ICU admission 15 (15, 16) 16 (15, 16) 15 (14, 15) 0.129
CVP, mmHg, 4 h after ICU admission 15 (15, 16) 15 (14, 16) 15 (15, 16) 0.425
CVP, mmHg, 6 h after ICU admission 14 (14, 15) 14 (14, 15) 14 (14, 15) 0.358
CVP, mmHg, 8 h after ICU admission 13 (13, 14) 13 (12, 14) 13 (12, 14) 0.801
MPAP, mmHg, After induction 25 (24, 27) 26 (24, 29) n = 61 25 (22, 29) n = 46 0.380
MPAP, mmHg, 30 minutes after CPB 25 (23, 27) 26 (23, 28) n = 76 25 (22, 27) n = 75 0.466
MPAP, mmHg, 30 minutes after CPB 26 (24, 27) 25 (23, 28) n = 104 26 (24, 28) n = 97 0.324
MPAP, mmHg, end of surgery 26 (25, 28) 26 (24, 28) n = 107 27 (24, 29) n = 94 0.659
MPAP, mmHg, ICU admission 29 (28, 30) 30 (29, 33) n = 113 27 (26, 29) n = 84 0.006
MPAP, mmHg, 2 h after ICU admission 30 (29, 31) 30 (29, 31) n = 120 29 (28, 31) n = 104 0.538
MPAP, mmHg, 4 h after ICU admission 30 (29, 31) 31 (29, 32) n = 126 29 (28, 30) n = 107 0.448
MPAP, mmHg, 6 h after ICU admission 29 (27, 29) 29 (27, 30) n = 125 28 (27, 30) n = 109 0.892
MPAP, mmHg, 8 h after ICU admission 28 (27, 29) 28 (26, 30) n = 128 28 (26, 30) n = 113 0.731
CI, L/min/m2, after induction 2.45 (2.24, 2.66) 2.46 (2.14, 2.77) n = 56 2.44 (2.17, 2.71) n = 38 0.947
CI, L/min/m2, 30 minutes before CPB 2.68 (2.57, 2.80) 2.62 (2.45, 2.79) n = 76 2.75 (2.58, 2.92) n = 75 0.269
CI, L/min/m2, 30 minutes after CPB 3.22 (3.08, 3.37) 3.14 (2.94, 3.34) n = 104 3.31 (3.09, 3.53) n = 97 0.261
CI, L/min/m2, end of surgery 3.02 (2.92-3.13) 2.95 (2.79, 3.11) n = 107 3.11 (2.97, 3.25) n = 94 0.140
CI, L/min/m2, ICU admission 2.80 (2.69, 2.92) 2.87 (2.73, 3.01) n = 113 2.71 (2.52, 2.89) n = 84 0.171
CI, L/min/m2, 2 h after ICU admission 3.06 (2.95, 3.17) 3.07 (2.92, 3.22) n = 120 3.05 (2.88, 3.21) n = 104 0.835
CI, L/min/m2, 4 h after ICU admission 3.12 (3.02, 3.23) 3.10 (2.98, 3.23) n = 126 3.15 (2.98, 3.32) n = 107 0.675
CI, L/min/m2, 6 h after ICU admission 3.24 (3.14, -3.35) 3.22 (3.10, 3.34) n = 125 3.27 (3.08, 3.46) n = 109 0.686
CI, L/min/m2, 8 h after ICU admission 3.18 (3.09, 3.28) 3.23 (3.11, 3.35) n = 128 3.13 (2.98, 3.28) n = 113 0.301
SvO2, %, after induction (n = 118) 79 (77, 80) 79 (78, 81) n = 61 77 (75, 79) n = 46 0.060
SvO2, %, 30 minutes before CPB (n = 147) 82 (81, 82) 82 (81, 83) n = 76 81 (80, 82) n = 75 0.357
SvO2, %, 30 minutes after CPB (n = 177) 78 (77, 79) 79 (77, 80) n = 104 78 (77, 80) n = 97 0.735
SvO2, %, end of surgery (n = 179) 77 (76, 78) 77 (76, 79) n = 107 77 (76, 79) n = 94 0.988
SvO2, %, ICU admission (n = 192) 71 (70, 72) 71 (70, 73) n = 113 70 (68, 72) n = 84 0.380
SvO2, %, 2 h after ICU admission (n = 287) 69 (68, 70) 69 (67, 70) n = 120 69 (67, 70) n = 104 0.931
SvO2, % 4 h after ICU admission (n = 309) 68 (67, 69) 67 (66, 69) n = 126 68 (67, 69) n = 107 0.322
SvO2, %, 6 h after ICU admission (n = 316) 69 (68, 70) 69 (68, 70) n = 125 69 (67, 70) n = 109 0.587
SvO2, %, 8 h after ICU admission 69 (68, 70) 69 (68, 71) n = 128 69 (67, 70) n = 113 0.264
Data are given as median/mean (95% confidence interval for the median/mean) as appropriate. HR: heart rate; MAP mean arterial blood pressure; CVP: central
venous pressure; MPAP: mean pulmonary arterial pressure; CI: cardiac index; SvO2: mixed venous oxygen saturation. MPAP, CI, and SvO2 were not available in
every patient.
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Table 5 Renal function and metabolism






Number 584 304 (52.1%) 280 (47.9%)
Diuresis and fluid balance
Postoperative diuresis within 24 h, ml 2,844 (2,744,
2,944)
2,723 (2,564, 2,881) 2,977 (2,861, 3,092) 0.012
Postoperative cristalloid fluid balance, ml -124 (-225,
-22)
-133 (-295, 30) -114 (-231, 4) 0.855
Postoperative surgical drainage, ml 927 (887, 968)] 933 (875, 991) 921 (865, 978) 0.782
Postoperative colloidals - drainage fluid balance, ml 549 (480, 618) 471 (374, 569) 633 (536, 731) 0.022
Postoperative diuretics, number of patients
Furosemide 280 (47.9%) 142 (46.7%) 138 (49.3%) 0.590
Torasemide 462 (79.1%) 242 (79.6%) 220 (78.6%) 0.838
HCT 200 (34.2%) 102 (33.6%) 98 (35.0%) 0.779
Other diuretics 34 (5.8%) 20 (6.6%) 14 (5.0%) 0.524
Renal function
Creatinine baseline, μmol/L 81 (79, 83) 81 (78, 84) 82 (78, 84) 0.787
Creatinine maximum*, μmol/L 93 (90, 96) 93 (88, 97) 93 (89, 97) 0.785
Creatinine at discharge*, μmol/L 82 (80, 87) 84 (80, 88) 80 (80, 87) 0.153
Maximum relative increase in creatinine*
< 25% 369 (63.2%) 204 (67.1%) 165 (58.9%) 0.217
> 25% 123 (21.1%) 57 (18.8%) 66 (23.6%)
> 50% 56 (9.6%) 25 (8.2%) 31 (11.1%)
> 100% 36 (6.2%) 18 (5.9%) 18 (6.4%)
eGFR baseline, ml/min 82 (80, 84) 81 (78, 84) 83 (80, 87) 0.434
eGFR minimum*, ml/min 69 (67, 71) 69 (66, 72) 70 (66, 73) 0.744
eGFR at discharge*, ml/min (n = 566) 82 (79, 85) 81 (77, 86) 83 (79, 86) 0.586
AKI grading according to creatinine changes (new RRT = grade
3), number patients
Grade 1 85 (14.6%) 38 (12.5%) 47 (16.8%) 0.478
Grade 2 7 (1.2%) 3 (1.0%) 4 (1.4%)
Grade 3 74 (12.7%) 39 (12.8%) 35 (12.5%)
AKI grading according to diuresis** (new RRT = grade 3), number
patients
Grade 1 14 (2.4%) 11 (3.6%) 3 (1.1%) 0.135
Grade 2 1 (0.2%) 0 (0.0%) 1 (0.4%)
Grade 3 45 (7.7%) 21 (6.9%) 24 (8.6%)
AKI grading, total**, number patients
Grade 1 90 (15.4%) 44 (14.5%) 46 (16.4%) 0.753
Grade 2 8 (1.4%) 3 (1.0%) 5 (1.8%)
Grade 3 75 (12.8%) 39 (12.8%) 36 (12.9%)
New RRT
Patients (%) 45 (7.7%) 22 (7.2%) 23 (8.2%) 0.774
Duration of treatment, h 144 (114, 196) 153 (110, 196) 125 (76, 227) 0.892
Intraoperative metabolism
Blood glucose max, mg/dl 193 (189, 202) 189 (184, 193) 197 (193, 204) 0.005
Blood glucose min, mg/dl 92 (91, 93) 91.5 (89, 94) 92 (91, 94) 0.181
pH max 7.45 (7.44,
7.45)
7.45 (7.45, 7.45) 7.45 (7.44, 7.45) 0.034
pH min 7.32 (7.32,
7.32)
7.32 (7.31, 7.32) 7.32 (7.32, 7.33) 0.157
Lactate max, mmol/L 1.7 (1.6, 1.8) 1.6 (1.5, 1.7) 1.8 (1.6, 1.9) 0.005
Lactate min, mmol/L 0.6 (0.6, 0.6) 0.6 (0.6, 0.7) 0.7 (0.6, 0.7) 0.594
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hemodynamic treatments differed markedly between the
groups. Patients in the BIC group were treated with more
crystalline and colloidal fluids, and more frequently and
with higher doses of noradrenaline (Table 3). No differ-
ences were observed in the use of inotropic drugs. No
differences in the rate of transfusion of packed red cells,
fresh frozen plasma, or thrombocyte concentrates were
observed.
Renal outcomes
Patients in the BIC group had a higher diuresis within
the first 24 h after surgery. No differences were
observed in the use of diuretics (Table 5). Renal replace-
ment therapy (RRT) was initiated in 7.2% of patients in
the CON and 8.2% of patients in the BIC group. Time
to initiation of RRT after ICU admission was 29.0 (19.0
to 39.0) h in the CON and 35.5 (24.5 to 49.0) h in the
BIC group (P not significant). The specific changes in
plasma creatinine, eGFR and the grading according to
the Acute Kidney Injury Network criteria are depicted
in Table 5.
General clinical outcomes
Despite comparable postoperative ventilation times,
duration of treatment in the ICU and in the high depen-
dency unit (HDU) were significantly prolonged in the
BIC group (Table 6). No differences in direct or indirect
measures of morbidity and mortality were observed
(Table 6).
Discussion
AKI is not only a frequent complication in cardiac sur-
gical patients [1] but has also been shown to be inde-
pendently associated with morbidity and mortality
[10,11]. Unfortunately, little progress has been made
within the last years in the development of strategies to
reduce the incidence and improve the prognosis of this
complication.
Recently, Haase and coworkers have elegantly deli-
neated a pathophysiological line of evidence that the
severity of the renal insult induced by on-pump cardiac
surgery may, at least in part, be related to the degree of
hemoglobinuria: the histological features of CSA-AKI
resemble the pigment nephropathy typically observed
during rhabdomyolysis [5]. Since alkalization of the
urine is among the established measures to treat rhab-
domyolysis [12] they used this concept successfully as a
strategy for the prevention of CSA-AKI in a small pilot
trial [7]. With respect to these promising findings, the
relatively high incidence of CSA-AKI at our institution,
the lack of other available measures for preventing renal
dysfunction during cardiac surgery [13], and the fact
that urine alkalization for the treatment of rhabdomyo-
lysis has a longstanding tradition in clinical medicine
[12], we chose to implement this concept into our clini-
cal routine. It is of note that an interdisciplinary work-
ing group on this topic also gave a positive
recommendation to use hydration and bicarbonate to
reduce the nephrotoxic effects of myo- and hemoglobi-
nuria [14].
In contrast to these promising findings, the results of
the present prospective observational cohort study show
that, in a heterogeneous patient population and under
the real life conditions of a University hospital, perio-
perative treatment with BIC does not reduce the inci-
dence of CSA-AKI as measured by postoperative
changes in creatinine, and the need for dialysis. More-
over, it is associated with clearly unwarranted effects
like a decrease in arterial blood pressure (during the
bolus application of BIC), an increased need for fluids
and vasopressors, and an increased need for treatment
in the HDU.
Table 5 Renal function and metabolism (Continued)
Postoperative metabolism
Blood glucose max, mg/dl 169.0 (166.0,
172.0)
163.5 (161.0, 167.0) 173.5 (170.12, 177.88) 0.0015
Blood glucose min, mg/dl 90.09
(88.68,1.51)
89.70 (87.73, 91.67) 90.53 (88.48, 92.57) 0.566
pH max 7.46 (7.46,
7.47]
7.46 (7.45, 7.46) 7.47 (7.46, 7.48) 0.001
pH min 7.32 (7.31,
7.32)
7.32 (7.31, 7.32) 7.32 (7.31, 7.33) 0.165
Lactate max, mmol/L 2.00 (1.90,
2.10)
1.90 (1.70, 2.00) 2.10 (2.00, 2.20) 0.010
Fluid balance, diuretics, metabolism, and renal function are shown for patients undergoing elective on-pump cardiac surgery with or without a perioperative
infusion of bicarbonate. HCT: hydrochlorothiazide; eGFR: estimated glomerular filtration rate: modifications of diet in renal disease formula; AKI: acute kidney
injury; CVVH: continuous-veno-venous hemofiltration; max: maximal; min: minimal. Data are given as absolute numbers (percentage) for nominal variables,
median (95% confidence interval) for non-normally distributed data, and mean (95% confidence interval) for normally distributed variables. *Changes in plasma
creatinine levels and derived variables were calculated after exclusion of patients treated with renal replacement therapy. **AKI grading was performed according
to Acute Kidney Injury Network recommendations (9) on the basis of changes in plasma creatinine, need for new renal replacement therapy and time course of
diuresis (within 48 h after surgery).
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The BIC dose chosen at our institution was compar-
able to the dose used by Haase and coworkers in their
pilot study [7]. However, they did not observe any
adverse effects or differences in the perioperative use of
fluids. Unfortunately, the doses of vasopressors and ino-
tropes used are not presented in this study.
With respect to the observational nature of our study,
we cannot completely rule out the possibility that the
adverse effects observed during the intervention period
were related to other, unmeasured variables. However, the
patient groups were ideally matched at baseline; not only
with respect to conventional demographic factors and sur-
gical procedures but also regarding the plasma levels of
established cardiovascular risk markers. The patients were
closely followed during the perioperative course, and a
relevant number of patients were monitored invasively
with a pulmonary arterial catheter to determine the car-
diac index and SvO2. We are also not aware of any other
clinical factor that was changed during this time: neither
the introduction of another, new clinical treatment nor
major changes in the treatment team. Thus it is rather
likely that the observed adverse effects in the intervention
period were indeed related to the use of bicarbonate
infusion, that is, alkalization, despite only achieving mini-
mal changes in maximal plasma pH.
Data show that BIC is frequently used in cardiac surgi-
cal patients to treat acidosis, especially during cardiopul-
monary bypass. Despite this, few data are available on the
short- and long-term hemodynamic effects of BIC.
Tripathi and coworkers observed a biphasic response
after the infusion of 1 mmol BIC/Kg BW during steady
state conditions during CPB with an immediate venous
pooling (leading to a decrease in the CPB reservoir
volume), followed by a moderate increase in MAP. In
contrast, observations in patients with end-stage renal
disease show that higher dialysate bicarbonate concentra-
tions lead to a decrease in arterial blood pressure during
dialysis [15], an effect that may be explained by an
increase in endothelial nitric oxide production [16].
Since the differences in maximal pH between the
study groups were rather small (0.1 pH difference)
despite being statistically significant, one may assume
that the lack of a nephroprotective effect of bicarbonate
infusion may be related to the fact that no adequate
alkalization was achieved. It is of note that Haase and
coworkers observed a mean difference in pH of 0.7
Table 6 Clinical course and complications
Total cohort Control - no bicarbonate Intervention - bicarbonate Significance, P-value
Number 584 304 (52.1%) 280 (47.9%)
Postoperative ventilation time, h 7 (7, 7) 7 (6, 8) 7 (7, 8) 0.234
Reintubation 46 (7.9%) 22 (7.2%) 24 (8.6%) 0.648
Tracheostomy 18 (3.1%) 8 (2.6%) 11 (3.6%) 0.677
Duration in ICU, h 23 (23, 24) 23 (22, 24) 24 (23, 24) 0.093
Duration in IMC, h 38 (27, 43) 27 (24, 42) 44 (36, 48) 0.0008
Duration in HDU, h 85 (73, 89) 83 (71, 88) 88 (72, 96) 0.026
Re-admission to ICU 19 (3.3%) 9 (3.0%) 10 (3.6%) 0.849
Need for CPR 10 (1.7%) 6 (2.0%) 4 (1.4%) 0.851
Reoperation 80 (13.7%) 45 (14.9%) 35 (12.5%) 0.492
MAC Score
1 54 (9.2%) 25 (8.2%) 29 (10.4%) 0.728
2 25 (4.3%) 14 (4.6%) 11 (3.9%)
3 10 (1.7%) 5 (1.6%) 5 (1.8%)
4 1 (0.2%) 0 (0.0%) 1 (0.4%)
Status upon discharge from hospital
Extubated 551 (94.3%) 290 (95.4%) 261 (93.2%) 0.377
Intubated 10 (1.7%) 2 (0.7%) 8 (2.9%)
Tracheostomy 13 (2.2%) 7 (2.3%) 6 (2.1%)
Died in hospital 8 (1.4%) 4 (1.3%) 4 (1.4%)
Status after 30 days
Dead 11 (1.9%) 5 (1.6%) 6 (2.1%) 0.573
Alive 572 (97.9%) 298 (98.0%) 274 (97.9%)
Unknown 1 (0.2%) 1 (0.3%) 0 (0.0%)
Postoperative course, complications, and clinical outcomes are shown in patients undergoing elective on-pump cardiac surgery with or without a perioperative
infusion of bicarbonate. CPR: cardiopulmonary resuscitation; MAC score: 1 point for each of the following complications - low cardiac output syndrome, stroke,
new need for renal replacement therapy, reintubation; IMC: intermediate care unit; HDU: high dependency unit. Data are given as absolute numbers (percentage)
for nominal variables, median (95% confidence interval) for non-normally distributed data, and mean (95% confidence interval ) for normally distributed variables.
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(7.38 to 7.45) [7] between the intervention and the con-
trol group with the same dose of bicarbonate. This dis-
crepancy may be related to the fact that we did not
record mean pH in the intra- and postoperative period,
which would probably have better reflected the differ-
ences in this variable in comparison between the control
and the intervention group.
As an important difference in comparison with the
previous pilot study [7] we did not specifically treat only
patients at risk for CSA-AKI, since the identification of
such patients is not trivial with respect to the multifac-
torial nature of this complication. Median CPB duration,
an accepted risk factor for CSA-AKI, was relatively long
in the present study population, suggesting that our
patients may be regarded as at risk per se. Nonetheless,
the risk for AKI attributable to prolonged CPB is prob-
ably lower than the risk of selected groups of patients
presenting with multiple risk factors for AKI. Conse-
quently our findings do not rule out the possibility that
a perioperative BIC infusion may be nephroprotective in
selected, especially vulnerable cardiac surgery patients,
as are currently being recruited for the BIC-NC study.
Comparably, we cannot rule out that the minor effect
of the BIC infusion on plasma pH in our study in com-
parison with Haase’s work may be related to the differ-
ent types of crystalloid infusions used: 0.9% sodium
chloride in the Australian setting [7] and a balanced
electrolyte infusion containing 24 mmol/L actetate in
our study. Thus, one may speculate that the use of
balanced fluids may reduce the effectiveness of BIC as a
measure to prevent CSA-AKI, in comparison with the
clinical setting in Australia in which patients were trea-
ted with more acidic solutions [7]. Interestingly, acetate
itself does also have vasodilating properties [17]. Conse-
quently, the higher doses of crystalloid solutions used in
the intervention group may also have aggravated the
vasodilatation (that is, the higher need for vasopressors)
observed in the intervention period.
Limitations
Despite all efforts to follow the patients meticulously
and to rule out other factors that may have influenced
our results, the design of this study as an observational
cohort study has a substantial risk of bias. The present
ongoing BIC-NC study (Clinical trials identifier
NCT00672334) will help to elucidate further, the risks
and benefits of using BIC to prevent AKI in patients
undergoing cardiac surgery.
With respect to the observational nature of this study
we did not perform an a priori power analysis to deter-
mine if the sample size is adequate. However, we
enrolled more patients than planned for the BIC-NC
study and additionally tested the endpoint, namely, 25%
increase in plasma creatinine, suggesting that our data-
set is adequately powered.
Conclusion
In conclusion, the present prospective observational trial
failed to reproduce the beneficial effects of a 24-h perio-
perative infusion of 4 mmol/Kg BIC on the incidence of
AKI in patients undergoing cardiac surgery, that were
recently shown in a small pilot trial. Routine treatment
in a heterogeneous cohort with BIC was associated with
an increased need for fluids and vasopressors. If this is a
direct effect of BIC infusion, or the indirect effect of an
associated treatment with balanced crystalloid solutions
containing the vasodilating buffer acetate, merits further
investigation.
Key messages
• The routine perioperative infusion of 4 mmol /Kg
BW sodium failed to reduce the incidence of acute
kidney injury and the need for renal replacement
therapy in a heterogeneous cohort of cardiac surgical
patients.
• Treatment with BIC was associated with hypoten-
sion, a higher need for vasopressors, and a prolonged
stay in the HDU but had no other significant adverse
effects on non-renal morbidity and 30-day mortality.
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